Pneumocystosis (PCP)

Categories: Infectious diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Pneumocystosis

MalaCards integrated aliases for Pneumocystosis:

Name: Pneumocystosis 12 73 20 58 15 17 32
Pneumocystis Jirovecii Pneumonia 12 20 3
Pneumocystis Carinii Pneumonia 12 20 15
Pneumocystis Pneumonia 12 20 3
Pcp 48 3
Pneumocystis Jiroveci Pneumonia 70
Pneumonia Pneumocystis Carinii 54
Pneumocystosis Pneumonia 12
Pulmonary Pneumocystosis 12
Pneumonia, Pneumocystis 44


Orphanet epidemiological data:

Inheritance: Not applicable; Age of death: any age;


Orphanet: 58  
Rare infectious diseases

External Ids:

Disease Ontology 12 DOID:11339
ICD9CM 34 136.3
MeSH 44 D011020
NCIt 50 C3334
SNOMED-CT 67 57541005
ICD10 32 B59
ICD10 via Orphanet 33 B59+ J17.3*
UMLS via Orphanet 71 C1535939
Orphanet 58 ORPHA723
UMLS 70 C1535939

Summaries for Pneumocystosis

CDC : 3 Pneumocystis pneumonia (PCP) is a serious infection caused by the fungus Pneumocystis jirovecii. Most people who get PCP have a medical condition that weakens their immune system, like HIV/AIDS, or take medicines that lower the body's ability to fight germs and sickness. In the United States, people with HIV/AIDS are less likely to get PCP today than before the availability of antiretroviral therapy (ART). However, PCP is still a substantial public health problem.1-3 Much of the information we have about PCP and its treatment comes from caring for patients with HIV/AIDS. Scientists have changed both the classification and the name of this organism since it first appeared in patients with HIV in the 1980s. Pneumocystis jirovecii used to be classified as a protozoan but is now considered a fungus.4 Pneumocystis jirovecii used to be called Pneumocystis carinii. When scientists renamed P. carinii to P. jirovecii, some people considered using the abbreviation "PJP," but to avoid confusion, Pneumocystis jirovecii pneumonia is still abbreviated "PCP."5

MalaCards based summary : Pneumocystosis, also known as pneumocystis jirovecii pneumonia, is related to immunodeficiency with hyper-igm, type 1 and oral candidiasis. An important gene associated with Pneumocystosis is DHPS (Deoxyhypusine Synthase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Methylprednisolone and Methylprednisolone hemisuccinate have been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and bone marrow, and related phenotypes are fever and hypoxemia

Disease Ontology : 12 An opportunistic mycosis that is located in lungs, but can also occur in eyes, ears, skin, thyroid, pituitary, palate, parathyroid, esophagus, pleura, heart, liver, spleen, small intestine, adrenals, kidneys, bone marrow, and lymph nodes, has material basis in Pneumocystis jirovecii that effects interstitial and alveolar tissues and has symptom nonproductive cough, has symptom shortness of breath, and has symptom fever.

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 723 Definition Human pneumocystosis is caused by an infectious agent, which (after recent nomenclature and taxonomy revisions) is now classed as the fungus Pneumocystis jiroveci. The prevalence is unknown. Pneumocystis jiroveci is an opportunistic infectious agent, developing in immunosuppressed patients. It is an air-borne infection, localised to the lungs. However, extrapulmonary involvement is seen in AIDS patients. The disease manifests progressively with coughing, respiratory problems (dyspnea) and fever, followed by acute respiratory insufficiency and death within a few weeks in untreated cases. The most reliable diagnostic method is bronchoalveolar lavage. The treatment of choice is cotrimoxazole.

Wikipedia : 73 Pneumocystosis is an infection by Pneumocystis jirovecii, that primarily occurs as a pulmonary infection... more...

Related Diseases for Pneumocystosis

Diseases related to Pneumocystosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1074)
# Related Disease Score Top Affiliating Genes
1 immunodeficiency with hyper-igm, type 1 31.9 CD8A CD40LG CD4 CCR6 BTK
2 oral candidiasis 31.1 CLEC7A CD4 CCR6 CARD9
3 nocardiosis 30.8 TNF CRP CD4
4 adult respiratory distress syndrome 30.8 TNF SFTPD IL6 CSF3
5 severe cutaneous adverse reaction 30.8 TNF CRP CD8A CD4
6 pyoderma gangrenosum 30.7 TNF CSF3 CCR6
7 posterior scleritis 30.7 TNF CRP
8 pancytopenia 30.7 IL6 DHFR CSF3 CRP CD8A CD4
9 extrinsic allergic alveolitis 30.6 SFTPD IL6 CCR6 ALB
10 autoimmune glomerulonephritis 30.6 CD8A CD4 CCR6
11 genital herpes 30.6 CD8A CD4 CCR6
12 pulmonary edema 30.6 TNF CSF3 CRP
13 scleritis 30.6 TNF CRP CCR6
14 adult t-cell leukemia 30.6 IL2 CD4 CCR6
15 pustulosis of palm and sole 30.6 TNF CRP CCR6
16 haemophilus influenzae 30.6 TNF CLEC7A
17 endocarditis 30.6 TNF IL6 CRP ALB
18 purpura 30.6 TNF IL6 CRP
19 drug allergy 30.6 CRP CD4 ALB
20 clostridium difficile colitis 30.6 CRP CCR6 ALB
21 esophageal candidiasis 30.5 CLEC7A CD8A CD4 CCR6 CARD9
22 end stage renal disease 30.5 TNF IL6 CRP ALB
23 toxoplasmosis 30.5 TNF IL6 DHFR CD40LG
24 severe acute respiratory syndrome 30.5 TNF IL6 CRP
25 pleural empyema 30.5 IL6 CRP CD4 ALB
26 disseminated intravascular coagulation 30.5 TNF IL6 CRP
27 hepatitis a 30.5 TNF CD4 ALB
28 miliary tuberculosis 30.4 TNF CSF3 CRP CD8A CD4 ALB
29 allergic disease 30.4 TNF IL6 IL2 CCR6
30 granulomatosis with polyangiitis 30.4 TNF CRP CD4 CCR6
31 iga glomerulonephritis 30.4 IL6 CD40LG CCR6 ALB
32 chronic urticaria 30.4 TNF IL6 CRP
33 chronic granulomatous disease 30.4 TNF MT-CYB CSF3 CD40LG
34 trypanosomiasis 30.4 TNF IL6 CSF3 ALB
35 t cell deficiency 30.4 IL2 CD8A CD4 CCR6
36 coccidioidomycosis 30.3 CLEC7A CD4 CCR6 CARD9
37 bacterial pneumonia 30.3 TNF SFTPD IL6 CSF3 CRP CD8A
38 substance abuse 30.3 IL6 CRP CD4 CCR6 ALB
39 urticaria 30.3 TNF IL6 CRP CD4
40 hypopyon 30.3 TNF IL6 CRP CD4
41 portal hypertension 30.3 TNF CD4 ALB
42 agammaglobulinemia, x-linked 30.3 CD40LG CD4 CCR6 BTK
43 mycobacterium tuberculosis 1 30.3 TNF CLEC7A CD8A CD4 CCR6
44 histoplasmosis 30.3 TNF CLEC7A CD8A CD4 CCR6
45 erythema multiforme 30.3 TNF IL6 IL2
46 herpes zoster 30.2 TNF IL2 DHFR CD8A CD4 CCR6
47 alcoholic hepatitis 30.2 TNF IL6 CRP ALB
48 goodpasture syndrome 30.2 CD52 CD4 CCR6 ALB
49 systemic autoimmune disease 30.2 IL6 CRP
50 marginal zone b-cell lymphoma 30.2 CD40LG CCR6 BTK

Comorbidity relations with Pneumocystosis via Phenotypic Disease Network (PDN):

Deficiency Anemia Heart Disease
Neutropenia Oral Candidiasis
Postinflammatory Pulmonary Fibrosis Respiratory Failure

Graphical network of the top 20 diseases related to Pneumocystosis:

Diseases related to Pneumocystosis

Symptoms & Phenotypes for Pneumocystosis

Human phenotypes related to Pneumocystosis:

58 31 (show all 25)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
2 hypoxemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0012418
3 acute infectious pneumonia 58 31 hallmark (90%) Very frequent (99-80%) HP:0011949
4 pneumocystis jirovecii pneumonia 58 31 hallmark (90%) Very frequent (99-80%) HP:0020102
5 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721
6 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
7 respiratory failure 58 31 frequent (33%) Frequent (79-30%) HP:0002878
8 respiratory failure requiring assisted ventilation 58 31 frequent (33%) Frequent (79-30%) HP:0004887
9 pleural effusion 58 31 frequent (33%) Frequent (79-30%) HP:0002202
10 exertional dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002875
11 interstitial pneumonitis 58 31 frequent (33%) Frequent (79-30%) HP:0006515
12 nonproductive cough 58 31 frequent (33%) Frequent (79-30%) HP:0031246
13 abnormal neutrophil count 58 31 frequent (33%) Frequent (79-30%) HP:0011991
14 combined cystic and ground-glass pattern on pulmonary hrct 58 31 frequent (33%) Frequent (79-30%) HP:0025395
15 increased circulating antibody level 31 frequent (33%) HP:0010702
16 neoplasm 58 31 occasional (7.5%) Occasional (29-5%) HP:0002664
17 chronic oral candidiasis 58 31 occasional (7.5%) Occasional (29-5%) HP:0009098
18 parenchymal consolidation 58 31 occasional (7.5%) Occasional (29-5%) HP:0032177
19 multiple pulmonary cysts 58 31 occasional (7.5%) Occasional (29-5%) HP:0005948
20 bloodstream infectious agent 58 31 occasional (7.5%) Occasional (29-5%) HP:0031863
21 increased lactate dehydrogenase level 31 occasional (7.5%) HP:0025435
22 respiratory insufficiency 58 Frequent (79-30%)
23 dyspnea 58 Very frequent (99-80%)
24 increased antibody level in blood 58 Frequent (79-30%)
25 increased lactate dehydrogenase activity 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Pneumocystosis:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 BTK CARD9 CCR6 CD4 CD40LG CD8A
2 homeostasis/metabolism MP:0005376 9.83 ALB BTK CARD9 CCR6 CD4 CD40LG
3 immune system MP:0005387 9.55 ALB BTK CARD9 CCR6 CD4 CD40LG

Drugs & Therapeutics for Pneumocystosis

Drugs for Pneumocystosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 468682 2826718
Sulfisoxazole Approved, Vet_approved Phase 4 127-69-5 5344
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
9 Anti-Retroviral Agents Phase 4
10 Protective Agents Phase 4
11 Methylprednisolone Acetate Phase 4
12 Antiemetics Phase 4
13 Gastrointestinal Agents Phase 4
14 Neuroprotective Agents Phase 4
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
Zidovudine Approved Phase 3 30516-87-1 35370
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
Hydroxychloroquine Approved Phase 3 118-42-3 3652
Cobicistat Approved Phase 3 1004316-88-4
Darunavir Approved Phase 3 635728-49-3, 206361-99-1 213039
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
Posaconazole Approved, Investigational, Vet_approved Phase 3 171228-49-2 147912
Trimetrexate Approved, Investigational Phase 3 52128-35-5 5583
leucovorin Approved Phase 3 58-05-9 6006
Isoniazid Approved, Investigational Phase 2, Phase 3 54-85-3 3767
Rezafungin Investigational Phase 3 1396640-59-7
Pafuramidine Investigational Phase 3 186953-56-0
Maleic acid Experimental Phase 3 110-16-7 444266
29 Reverse Transcriptase Inhibitors Phase 3
30 Antirheumatic Agents Phase 3
31 Anti-HIV Agents Phase 3
32 Antiviral Agents Phase 3
33 Cytochrome P-450 CYP3A Inhibitors Phase 3
34 HIV Protease Inhibitors Phase 3
protease inhibitors Phase 3
36 Echinocandins Phase 3
37 Antimetabolites Phase 3
38 Antidotes Phase 3
39 Micronutrients Phase 3
40 Trace Elements Phase 3
41 Nutrients Phase 3
42 Vitamins Phase 3
43 Calcium, Dietary Phase 3
44 Lipid Regulating Agents Phase 2, Phase 3
45 Hypolipidemic Agents Phase 2, Phase 3
Calcium Nutraceutical Phase 3 7440-70-2 271
Vitamin K1 Approved, Investigational Phase 2 84-80-0 5284607
Ganciclovir Approved, Investigational Phase 1, Phase 2 82410-32-0 3454
Triamcinolone Approved, Vet_approved Phase 1, Phase 2 124-94-7 31307
Mycophenolic acid Approved Phase 1, Phase 2 24280-93-1 446541

Interventional clinical trials:

(show top 50) (show all 83)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Gradual Initiation of Trimethoprim/Sulfamethoxazole as Primary Pneumocystis Carinii Pneumonia Prophylaxis Completed NCT00000816 Phase 4 Sulfamethoxazole-Trimethoprim
3 Randomized Clinical Trial to Assess Whether the Duration of Cotrimoxazole Preventive Therapy in HIV Patients With CD4 Counts >350 CD4 Cells/µL by Antiretroviral Treatment Influences the Rate of Carriage of Multidrug-resistant Bacteria Completed NCT03087890 Phase 4 Cotrimoxazole;Placebo
4 A Prospective Randomized Controlled Study to Compare Efficacy of Caspofungin Combined With Trimethoprim-sulfamethoxazole Versus Trimethoprim/Sulfamethoxazole as First-line Therapy in Non-HIV Patients With Severe Pneumocystis Pneumonia Recruiting NCT03978559 Phase 4 caspofungin;TMP/SMZ(trimethoprim/sulfisoxazole);Methylprednisolone
5 Oral Corticosteroids Therapy and Interstitial Fibrosis in Patients With Pneumocystis Jirovecii Pneumonia (PCP) and pO2 of >70 at Presentation. Withdrawn NCT00636935 Phase 4 Antibiotics only;Antibiotics + Corticosteroids;Corticosteroids + antibiotics
6 The Safety and Effectiveness of Trimethoprim/Sulfamethoxazole as Pneumocystis Carinii Pneumonia (PCP) Prophylaxis in Patients With Connective Tissue Diseases Unknown status NCT01747278 Phase 2, Phase 3 Trimethoprim/Sulfamethoxazole
7 A Randomized, Open-Label Trial of High Dose Atovaquone Versus Low Dose Atovaquone Versus Aerosolized Pentamidine for Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With HIV Infection Who Are Intolerant of TMP/SMX Completed NCT00002340 Phase 3 Atovaquone;Pentamidine isethionate
8 A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS Completed NCT00001014 Phase 3 Trimetrexate glucuronate;Sulfamethoxazole-Trimethoprim;Leucovorin calcium
9 A Controlled Comparative Trial of Trimethoprim - Sulfamethoxazole Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT) Completed NCT00000727 Phase 3 Pentamidine isethionate;Pyrimethamine;Sulfamethoxazole/Trimethoprim;Sulfadoxine/Pyrimethamine;Zidovudine
10 An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies Completed NCT00000714 Phase 3 Trimetrexate glucuronate;Leucovorin calcium
11 A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies Completed NCT00001016 Phase 3 Trimetrexate glucuronate;Leucovorin calcium
12 A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS Completed NCT00001013 Phase 3 Trimetrexate glucuronate;Pentamidine isethionate;Sulfamethoxazole-Trimethoprim;Leucovorin calcium
13 A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis Carinii Pneumonia Completed NCT00000724 Phase 3 Trimetrexate glucuronate;Leucovorin calcium
14 A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Pneumonia in AIDS Completed NCT00000715 Phase 3 Pentamidine isethionate;Sulfamethoxazole-Trimethoprim
15 A Randomized, Comparative, Prospective Study of Monthly Aerosolized Pentamidine and Thrice Weekly Dapsone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant to Trimethoprim and/or Sulfonamides Completed NCT00001028 Phase 3 Pentamidine isethionate;Dapsone
16 A Randomized Trial of Three Anti-Pneumocystis Agents Plus Zidovudine for the Primary Prevention of Serious Infections in Patients With Advanced HIV Infection Completed NCT00000991 Phase 3 Pentamidine isethionate;Sulfamethoxazole-Trimethoprim;Dapsone;Zidovudine
17 A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients Completed NCT00000748 Phase 3 Sulfamethoxazole-Trimethoprim
18 A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides Completed NCT00000802 Phase 3 Atovaquone;Dapsone
19 A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Trimethoprim / Sulfamethoxazole in the Treatment of Mild-to-Moderate PCP in Patients With AIDS Completed NCT00000640 Phase 3 Primaquine;Sulfamethoxazole-Trimethoprim;Dapsone;Clindamycin
20 Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19 Completed NCT04261517 Phase 3 Hydroxychloroquine
21 Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19 Recruiting NCT04252274 Phase 3 Darunavir and Cobicistat
22 A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study) Recruiting NCT04368559 Phase 3 Rezafungin for Injection;Posaconazole;Fluconazole;Trimethoprim-sulfamethoxazole (TMP/SMX);Intravenous Placebo;Oral Placebo
23 Intérêt de la corticothérapie Dans la Pneumocystose Grave du Patient immunodéprimé Non VIH. Essai Prospectif Multicentrique Randomisé Contrôlé : PIC Recruiting NCT02944045 Phase 3 Methylprednisolone;Placebo
24 A Randomized, Comparative Trial of Trimetrexate With Leucovorin Rescue Versus Standard Anti-Pneumocystis Therapy Versus Standard Anti-Pneumocystis Therapy With High Dose Steroids for AIDS Patients With Pneumocystis Pneumonia Who Appear to Be Refractory to Conventional Drugs Terminated NCT00000730 Phase 3 Trimetrexate glucuronate;Methylprednisolone;Pentamidine isethionate;Sulfamethoxazole-Trimethoprim;Leucovorin calcium
25 International Randomized, Controlled Phase 3 Trial of DB289 Versus Trimethoprim-sulfamethoxazole for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) in Patients With HIV/AIDS Terminated NCT00302341 Phase 3 Pafuramidine maleate (DB289);Trimethoprim-Sulfamethoxazole (TMP-SMX)
26 A Randomized, Double Blind, Placebo Controlled Trial to Determine the Efficacy of Isoniazid (INH) in Preventing Tuberculosis Disease and Latent Tuberculosis Infection Among Infants With Perinatal Exposure to HIV Terminated NCT00080119 Phase 2, Phase 3 Isoniazid (INH);Trimethoprim/Sulfamethoxazole (TMP/SMX);Isoniazid Placebo (PL)
27 A Controlled Randomized Trial to Study the Efficacy of Adjunctive Methylprednisolone for the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Pediatric AIDS Patients Withdrawn NCT00000741 Phase 3 Methylprednisolone
28 A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole Completed NCT00001996 Phase 2 Atovaquone;Pentamidine isethionate
29 A Phase II Study of WR 6026 for Pneumocystis Carinii Pneumonia in People With HIV Infection Completed NCT00000863 Phase 2 Sitamaquine
30 A Randomized, Double-Blind Study of 566C80 Versus Septra (Trimethoprim/Sulfamethoxazole) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Completed NCT00000655 Phase 2 Atovaquone;Sulfamethoxazole-Trimethoprim
31 Randomized, Multi-Center Comparative Trial of Tacrolimus w/Steroids and Standard Daclizumab Induction vs a Novel Steroid-Free Tacrolimus Based Immunosuppression Protocol w/ Extended Daclizumab Induction in Pediatric Renal Transplantation Completed NCT00141037 Phase 1, Phase 2 Daclizumab;Mycophenolate mofetil (MMF);Prednisone;Tacrolimus;Ganciclovir;Valganciclovir;Trimethoprim and sulfamethoxazole
32 A Randomized, Phase II/III, Double-Blind, Two-Armed Study of Micronized Atovaquone and Azithromycin (AT/AZ) as Compared to Trimethoprim-Sulfamethoxazole (TMP/SMX) in the Prevention of Serious Bacterial Infections When Used in Children Aged 3 Months to 19 Years With HIV Infection Completed NCT00000811 Phase 2 Azithromycin;Atovaquone;Sulfamethoxazole-Trimethoprim
33 Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia Completed NCT00002120 Phase 1 Trimetrexate glucuronate;Trimethoprim;Sulfamethoxazole;Dapsone;Leucovorin calcium
34 A Phase I Study of the Safety, Tolerance, and Study of the Pharmacokinetics of Aerosolized Pentamidine and Parenteral Pentamidine in Children With HIV Infection and Suspected Pneumocystis Carinii Pneumonia Completed NCT00000974 Phase 1 Pentamidine isethionate
35 Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection Completed NCT00000739 Phase 1 Dapsone
36 Evaluation of Escalating Doses of Intravenous Trimetrexate as Therapy for Previously Untreated Pneumocystis Carinii Pneumonia in AIDS Patients With Subsequent Comparison of Intravenous and Oral Pharmacokinetics Completed NCT00000998 Phase 1 Trimetrexate glucuronate;Leucovorin calcium
37 A Phase I/II Trial of Parenteral Pentamidine for PCP Prophylaxis in HIV-Infected Children Who Are Intolerant to Oral Trimethoprim-Sulfamethoxazole Completed NCT00001027 Phase 1 Pentamidine isethionate
38 Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children Completed NCT00000773 Phase 1 Atovaquone
39 Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects Completed NCT00000740 Phase 1 Sitamaquine
40 A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-trimethoprim Therapy Unknown status NCT02045160
41 Prospective Registration of Severe Pneumocystis Jiroveci Pneumonia Requiring ICU Unknown status NCT03201497
42 Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU Completed NCT04368221
43 Clindamycin - Trimethoprim/Sulfamethoxazole for Pneumocystis Jiroveci Pneumonia After Solid Organ Transplantation Population (CTSTOP) Completed NCT04328688
44 A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia Completed NCT00002103 Trimetrexate glucuronate;Leucovorin calcium
45 A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia. Completed NCT00002102 Trimetrexate glucuronate;Leucovorin calcium
46 A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral / Oral Trimethoprim - Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia in AIDS Completed NCT00002056 Pentamidine isethionate
47 A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients With Multiple Episodes of PCP Completed NCT00002055 Pentamidine isethionate
48 A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Completed NCT00002054 Pentamidine isethionate
49 A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP Completed NCT00002053 Pentamidine isethionate
50 Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC) Completed NCT00002043 Dapsone

Search NIH Clinical Center for Pneumocystosis

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Pentamidine Isethionate

Cochrane evidence based reviews: pneumonia, pneumocystis

Genetic Tests for Pneumocystosis

Anatomical Context for Pneumocystosis

MalaCards organs/tissues related to Pneumocystosis:

Lung, Kidney, Bone Marrow, Bone, Skin, Small Intestine, Spleen

Publications for Pneumocystosis

Articles related to Pneumocystosis:

(show top 50) (show all 2218)
# Title Authors PMID Year
Absence of Pneumocystis jirovecii dihydropteroate synthase gene mutations among samples from a group of AIDS patients in China. 61 54
19085210 2009
Structural analysis of a holoenzyme complex of mouse dihydrofolate reductase with NADPH and a ternary complex with the potent and selective inhibitor 2,4-diamino-6-(2'-hydroxydibenz[b,f]azepin-5-yl)methylpteridine. 54 61
18703847 2008
Caspase-9 as a target for Pneumocystis pneumonia therapy. 54 61
17169033 2006
Pneumocystosis: survey and DHPS genotype analysis in 14 Parisian hospitals in 2003 and 2004. 61 54
17169018 2006
Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. 54 61
15867494 2005
Cloning of the Pneumocystis jirovecii trifunctional FAS gene and complementation of its DHPS activity in Escherichia coli. 54 61
15531210 2004
Pneumocystis jiroveci isolates with dihydropteroate synthase mutations in patients with chronic bronchitis. 54 61
15175932 2004
Pneumocystis jirovecii dihydropteroate synthase genotypes in immunocompetent infants and immunosuppressed adults, Amiens, France. 54 61
15200857 2004
Pneumocystis jirovecii dihydropteroate synthase genotypes in French patients with pneumocystosis: a 1998-2001 prospective study. 61 54
14725329 2003
Multilocus genotyping of Pneumocystis jirovecii in patients developing diverse forms of parasitism: implication for a wide human reservoir for the fungus. 54 61
14736212 2003
Pneumocystis carinii pneumonia in a term newborn infant with a transiently depressed T lymphocyte count, primarily of cells carrying the CD4 antigen. 61 54
8496763 1993
Blood urea nitrogen-to-serum albumin ratio and A-DROP are useful in assessing the severity of Pneumocystis pneumonia in patients without human immunodeficiency virus infection. 61
33376033 2021
Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection. 61
33277811 2021
Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study. 61
33571651 2021
Adverse effects of trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis pneumonia in dermatology. 61
33492693 2021
Role of Serum (1,3)-Β-D-Glucan to Screen for Pneumocystis Pneumonia in Kidney Transplant Recipients. 61
32928557 2021
The diagnostic challenge of pneumocystis pneumonia and COVID-19 co-infection in HIV. 61
33664959 2021
Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis. 61
33495923 2021
Genomic insights into the host specific adaptation of the Pneumocystis genus. 61
33686174 2021
Pneumocystis pneumonia: An important consideration when investigating artificial intelligence-based methods in the radiological diagnosis of COVID-19. 61
33810937 2021
Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases. 61
33688083 2021
Direct and indirect evidence of efficacy and safety of rapid exercise tests for exertional desaturation in Covid-19: a rapid systematic review. 61
33726854 2021
Estimates of serious fungal infection burden in Côte d'Ivoire and country health profile. 61
33259981 2021
A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era. 61
33211356 2021
Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia. 61
33318018 2021
A single-centre, retrospective study of the incidence of invasive fungal infections during 85 years of autopsy service in Brazil. 61
33597620 2021
Exploring genetic defects in adults who were clinically diagnosed as severe combined immune deficiency during infancy. 61
33599911 2021
The impact of COVID-19 pandemic on AIDS-related mycoses and fungal neglected tropical diseases: Why should we worry? 61
33561159 2021
Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap. 61
33676765 2021
A proposal for pragmatic investigation of possible clonal clusters of pneumocystis pneumonia cases. 61
33271216 2021
Intravenous immunoglobulin as adjunctive therapy in kidney transplant recipients with severe pneumocystis pneumonia. 61
32869412 2021
Pneumocystis Pneumonia: Immunity, Vaccines, and Treatments. 61
33669726 2021
[Dihydropteroate Synthase (DHPS) Gene Mutations and Mitochondrial Large Subunit (mtLSU) rRNA Genotype Variations in Pneumocystis jirovecii Strains]. 61
33590980 2021
COVID-19 and its Mimics: What the Radiologist Needs to Know. 61
32852419 2021
Toward a humanized mouse model of Pneumocystis pneumonia. 61
33491669 2021
Pneumocystis pneumonia with hypogammaglobulinemia in a pediatric patient who underwent heart transplantation. 61
33470002 2021
Pneumocystis Pneumonia: Still a serious disease in children. 61
33759428 2021
Fine-needle aspiration of granulomatous pneumocystosis. 61
32621323 2021
[Pneumocystis pneumonia and HIV infection in two patients suspected with COVID-19]. 61
33491631 2021
[Early recurrence of pneumocystis pneumonia post trimethoprim-sulfamethoxazole therapy that developed after chemotherapy for follicular lymphoma]. 61
33551424 2021
Clinically amyopathic dermatomyositis presenting with isolated facial edema complicated by acute respiratory failure: a case report. 61
33509162 2021
[Spontaneous resolution of refractory ascites in the late phase after cord blood transplantation in acute myeloid leukemia]. 61
33551420 2021
Increased mRNA expression of key cytokines among suspected cases of Pneumocystis jirovecii infection. 61
33413198 2021
Pneumocystis jirovecii pneumonia in diffuse large B-cell Lymphoma treated with R-CHOP. 61
32970331 2021
X-linked CD40 ligand deficiency in a 1-year-old male Shih Tzu with secondary Pneumocystis pneumonia. 61
33274522 2021
[The spectrum of pathogens in 187 cases of pulmonary fungal disease diagnosed by histopathology-a retrospective analysis]. 61
33412621 2021
Characteristics and outcome according to underlying disease in non-AIDS patients with acute respiratory failure due to Pneumocystis pneumonia. 61
33411170 2021
Efficacy and safety of trimethoprim-sulfamethoxazole for the prevention of pneumocystis pneumonia in human immunodeficiency virus-negative immunodeficient patients: A systematic review and meta-analysis. 61
33765022 2021
Chest complications in immunocompromised patients without acquired immunodeficiency syndrome (AIDS): differentiation between infectious and non-infectious diseases using high-resolution CT findings. 61
32859382 2021
Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis. 61
32506311 2021

Variations for Pneumocystosis

Expression for Pneumocystosis

Search GEO for disease gene expression data for Pneumocystosis.

Pathways for Pneumocystosis

Pathways related to Pneumocystosis according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
13.78 TNF MUC1 IL6 IL2 CSF3 CD40LG
Show member pathways
13.36 TNF IL6 IL2 CSF3 CD40LG CD4
Show member pathways
13.32 TNF MUC1 IL6 IL2 CSF3 CD40LG
Show member pathways
13.25 TNF IL6 IL2 CSF3 CD40LG CD4
Show member pathways
12.81 TNF IL6 IL2 CD8A CD40LG CD4
Show member pathways
12.59 TNF IL2 CD40LG CD4 BTK
Show member pathways
12.56 TNF IL6 IL2 CD8A CD40LG CD4
10 12.29 TNF IL6 IL2 CD4
Show member pathways
12.28 TNF IL6 IL2 CCR6
Show member pathways
Show member pathways
15 12.01 TNF IL6 IL2 CD8A CD4
16 11.8 TNF IL6 CSF3 CD8A CD4
Show member pathways
11.75 TNF IL6 IL2 CD4
Show member pathways
Show member pathways
11.71 TNF IL2 CD40LG
20 11.7 TNF IL6 IL2 CSF3 CD8A CD4
21 11.67 TNF IL6 CD40LG CCR6
22 11.62 TNF IL6 CSF3
Show member pathways
11.62 TNF IL6 IL2 CD40LG
24 11.62 TNF IL2 CD8A CD4 CCR6
Show member pathways
11.6 TNF IL2 CD8A
26 11.52 TNF IL6 IL2 CD8A CD4
27 11.51 TNF IL6 IL2
28 11.49 TNF IL6 CSF3
29 11.49 TNF IL6 CSF3 CD40LG
30 11.31 CD8A CD40LG CD4 BTK
31 11.27 TNF IL6 DHFR
32 11.03 TNF IL6 CRP
33 10.99 TNF IL6 IL2 CSF3 CD40LG BTK
34 10.48 TNF IL6 IL2 CSF3 CD4

GO Terms for Pneumocystosis

Cellular components related to Pneumocystosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 TNF SFTPD MUC1 IL6 IL2 CSF3
2 external side of plasma membrane GO:0009897 9.55 TNF CD8A CD40LG CD4 CCR6
3 extracellular region GO:0005576 9.36 TNF SFTPD MUC1 IL6 IL2 CSF3

Biological processes related to Pneumocystosis according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 10 SFTPD CRP CLEC7A CLEC4E CARD9 BTK
2 inflammatory response GO:0006954 9.98 TNF IL6 CRP CLEC7A CD40LG
3 immune system process GO:0002376 9.92 SFTPD IL2 CLEC7A CLEC4E CD8A CD4
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.86 TNF IL6 CD40LG BTK
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 TNF IL6 IL2
6 positive regulation of interferon-gamma production GO:0032729 9.79 TNF IL2 CLEC7A
7 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.79 TNF CARD9 BTK
8 positive regulation of interleukin-8 production GO:0032757 9.77 TNF IL6 CLEC7A
9 humoral immune response GO:0006959 9.77 TNF IL6 CCR6
10 defense response to Gram-positive bacterium GO:0050830 9.76 TNF IL6 CRP CARD9
11 positive regulation of interleukin-1 beta production GO:0032731 9.75 TNF IL6 CLEC7A
12 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.74 TNF CLEC7A CARD9
13 cytokine-mediated signaling pathway GO:0019221 9.73 TNF MUC1 IL6 IL2 CSF3 CD4
14 positive regulation of phagocytosis GO:0050766 9.72 TNF SFTPD CLEC7A
15 T cell activation GO:0042110 9.71 CLEC7A CD8A CD4
16 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.71 IL6 CSF3 CLEC7A CD4
17 positive regulation of interleukin-6 production GO:0032755 9.67 TNF IL6 CLEC7A CARD9
18 positive regulation of interleukin-10 production GO:0032733 9.65 IL6 CLEC7A CD40LG
19 regulation of immunoglobulin production GO:0002637 9.63 TNF CD40LG
20 response to peptidoglycan GO:0032494 9.62 IL6 CARD9
21 vascular endothelial growth factor production GO:0010573 9.61 TNF IL6
22 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.61 TNF IL6 CLEC7A
23 immune response GO:0006955 9.56 TNF IL6 IL2 CSF3 CD8A CD40LG
24 cellular response to molecule of fungal origin GO:0071226 9.51 CLEC7A BTK
25 leukocyte activation involved in immune response GO:0002366 9.49 IL2 CLEC7A
26 negative regulation of lipid storage GO:0010888 9.33 TNF IL6 CRP
27 positive regulation of T cell proliferation GO:0042102 9.02 IL6 IL2 DHPS CD40LG CD4

Molecular functions related to Pneumocystosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.26 SFTPD IL2 CLEC7A CLEC4E
2 cytokine activity GO:0005125 9.02 TNF IL6 IL2 CSF3 CD40LG

Sources for Pneumocystosis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....